Medical Marijuana Competitive Intelligence Analysis, 2019” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across Medical Marijuana industry. A detailed picture of the competitive landscape is provided with summation of data from multiple sources with complete analysis of companies, patents, pipeline products, competitive benchmarking and therapeutic assessment of clinical products.
The fast development of the cannabis and its expanding appropriation over the therapeutic application has grabbed the eye of a large group of industry verticals running from pharmaceuticals to land and preparing ventures to advisory and consultancy administrations. While cannabis cultivators and producers are the most critical piece of the cannabis ecosystem, revenue comes significantly from Pharmaceutical organizations. The U.S. Food and Drug Administration (FDA) has not recognized or approved the marijuana plant as medicine. However, the scientific study of the chemicals in marijuana, called cannabinoids, has led to some FDA-approved medications that contain cannabinoid chemicals in pill form. Continued research may lead to the approval of more medications.
Check Medical Marijuana Market Size
The report covers 12+ companies working in this domain, such as GW Pharmaceuticals, Canopy Growth Corporation, Aurora Cannabis, Auxly Cannabis Group and others. GW Pharmaceuticals has two medical marijuana products in the market; Epidiolex and Sativex. Epidiolex (cannabidiol) oral solution is the first FDA-approved drug that contains a purified drug substance derived from marijuana. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. The company profiles include but are not limited to business overview, products, and latest development activities focusing on collaborations and licensing deals, partnerships and agreements, acquisitions, product launches, awards and grants, and other latest developments. The report comprises of comparative pipeline therapeutics assessment by development phase, indication, and route of administration. There are various products in late stages of development which point towards a hopeful future in terms of products approvals. Neuropathic pain has been the most sought after indication for clinical trials, followed by spasticity in patients with multiple sclerosis, cancer pain, and others.
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases. Data gathered from secondary sources has been validated through primary research methods, such as questionnaires and surveys by contacting industry experts and key opinion leaders (KOLs).
Source:- Medical Marijuana Market Share
Comments
Post a Comment